
Baxter (NYSE:BAX) offered European regulators concessions to lessen antitrust concerns over the $4 billion (26.5 billion SEK) acquisition of Swedish dialysis giant Gambro.
A Baxter spokesperson couldn’t comment on details of the proposal because negotiations with European regulators are still ongoing, but confirmed the company hopes to finalize a deal in Q3.
European Commission regulators have raised concerns that the joined companies might dominate the hemodialysis and kidney dialysis markets, but the merger has been approved by regulators in Brazil, Canada, South Korea, Turkey, the U.S.
Deerfield, Ill.-based Baxter is still waiting to hear back from Europe, China, the Ukraine and Australia. On Monday the European Commission extended until July 8 its deadline to review the proposal.
Baxter in December 2012 confirmed rumors of the Gambro buyout, inking the high-value deal after rumors of a possible deal began circulating just a month earlier.